These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1326 related items for PubMed ID: 8731505

  • 1. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
    Reisfeld RA, Gillies SD.
    J Clin Lab Anal; 1996; 10(3):160-6. PubMed ID: 8731505
    [No Abstract] [Full Text] [Related]

  • 2. [Immunotherapy of malignant diseases].
    Dorval T, Michon J, Tartour E, Fridman WH.
    Bull Cancer; 1995; 82 Suppl 2():127s-138s. PubMed ID: 7542946
    [Abstract] [Full Text] [Related]

  • 3. Pre-clinical models for immunotherapy of melanoma.
    Reisfeld RA.
    Prog Clin Biol Res; 1989; 288():183-93. PubMed ID: 2654950
    [No Abstract] [Full Text] [Related]

  • 4. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
    Melani C, Figini M, Nicosia D, Luison E, Ramakrishna V, Casorati G, Parmiani G, Eshhar Z, Canevari S, Colombo MP.
    Cancer Res; 1998 Sep 15; 58(18):4146-54. PubMed ID: 9751627
    [Abstract] [Full Text] [Related]

  • 5. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA, Hu P, Epstein AL.
    Handb Exp Pharmacol; 2008 Sep 15; (181):291-328. PubMed ID: 18071951
    [Abstract] [Full Text] [Related]

  • 6. Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer.
    Zhang X, Feng J, Ye X, Yao Y, Zhou P, Chen X.
    Gynecol Oncol; 2006 Dec 15; 103(3):848-52. PubMed ID: 16806435
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. T cells take aim at cancer.
    Pardoll D.
    Proc Natl Acad Sci U S A; 2002 Dec 10; 99(25):15840-2. PubMed ID: 12461164
    [No Abstract] [Full Text] [Related]

  • 10. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
    Liu A, Hu P, Khawli LA, Epstein AL.
    J Immunother; 2006 Dec 10; 29(4):425-35. PubMed ID: 16799338
    [Abstract] [Full Text] [Related]

  • 11. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D, Fong L.
    J Clin Oncol; 2005 Dec 10; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract] [Full Text] [Related]

  • 12. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
    Tomala J, Chmelova H, Mrkvan T, Rihova B, Kovar M.
    J Immunol; 2009 Oct 15; 183(8):4904-12. PubMed ID: 19801515
    [Abstract] [Full Text] [Related]

  • 13. [Immunotherapy of parenchymal tumors. Recent progress and theoretical considerations].
    Marincola F, Smolik L, Annoni F, Holter WD.
    Minerva Chir; 1988 Jul 31; 43(13-14):1111-31. PubMed ID: 3054627
    [No Abstract] [Full Text] [Related]

  • 14. Engineering mouse monoclonal antibodies for cancer immunotherapy.
    Orlandi R.
    Year Immunol; 1993 Jul 31; 7():69-73. PubMed ID: 8372514
    [No Abstract] [Full Text] [Related]

  • 15. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).
    Klehr M, Koehl U, Mühlenhoff M, Tawadros S, Fischer T, Schomäcker K, Heuckmann JM, Bochennek K, Jensen M.
    J Immunother; 2009 Jun 31; 32(5):442-51. PubMed ID: 19609236
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunocytokines: a new approach to immunotherapy of melanoma.
    Reisfeld RA, Becker JC, Gillies SD.
    Melanoma Res; 1997 Aug 31; 7 Suppl 2():S99-106. PubMed ID: 9578424
    [Abstract] [Full Text] [Related]

  • 19. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
    Soiffer RJ, Chapman PB, Murray C, Williams L, Unger P, Collins H, Houghton AN, Ritz J.
    Clin Cancer Res; 1997 Jan 31; 3(1):17-24. PubMed ID: 9815532
    [Abstract] [Full Text] [Related]

  • 20. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D.
    Cancer Res; 2003 Jun 15; 63(12):3202-10. PubMed ID: 12810649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.